The company reported solid Q2 sales of $64 million, maintained full year guidance, and announced a strategic acquisition of Sanara MedTech described as 'transformational' that accelerates their surgical expansion strategy. These developments indicate growth momentum and strategic progress.
Articles that tag MDXG but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
